Another point to consider is that if any cardiovascular benefit exists, then the optimal dosing and administration of GLP-1 agonists in different populations with a spectrum of different co-morbidities in addition to type 2 diabetes mellitus is still an unexplored path. The gene discussed is GCG; the disease is diabetes mellitus.